Agios to Webcast Conference Call of Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025

Rhea-AI Summary

Agios Pharmaceuticals (AGIO), a company focused on cellular metabolism and pyruvate kinase activation therapies for rare diseases, has announced it will host a conference call and live webcast to discuss its fourth quarter and full year 2024 financial results. The event is scheduled for Thursday, February 13, 2025, at 8:00 a.m. ET. The webcast will be available on the company's website under the Investors section, with a replay accessible approximately two hours after the event.

News Market Reaction – AGIO

+0.12%

+0.12% Session move

In the trading session that priced this news, AGIO gained 0.12%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to report its fourth quarter and full year 2024 financial results and business highlights.

The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.

About Agios
Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S., Agios markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for this rare, lifelong, debilitating hemolytic anemia. Building on the company's deep scientific expertise in classical hematology and leadership in the field of cellular metabolism and rare hematologic diseases, Agios is advancing a robust clinical pipeline of investigational medicines with programs in alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, myelodysplastic syndrome (MDS)-associated anemia and phenylketonuria (PKU). In addition to its clinical pipeline, Agios is advancing a preclinical TMPRSS6 siRNA as a potential treatment for polycythemia vera. For more information, please visit the company’s website at www.agios.com.

Contacts:
Investor Contact
Chris Taylor, VP, Investor Relations and Corporate Communications
Agios Pharmaceuticals
IR@agios.com

Media Contact
Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
Media@agios.com

FAQ

When will Agios (AGIO) report Q4 and full year 2024 earnings?

Agios Pharmaceuticals (AGIO) will report its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, at 8:00 a.m. ET.

How can investors access AGIO's Q4 2024 earnings call?

Investors can access the live webcast through the Investors section of Agios' website (www.agios.com) under the Events & Presentations tab.

Will AGIO's Q4 2024 earnings call be available for replay?

Yes, a replay of the webcast will be available on Agios' website approximately two hours after the event.

What will Agios (AGIO) discuss in their February 13, 2025 conference call?

Agios will discuss their fourth quarter and full year 2024 financial results and business highlights during the conference call.